Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy

B. Moriyama; A. Owusu Obeng; J. Barbarino; S. R. Penzak; S. A. Henning; S. A. Scott; J. A.G. Agúndez; J. R. Wingard; H. L. McLeod; T. E. Klein; S. J. Cross; K. E. Caudle; T. J. Walsh

doi:10.1002/cpt.583

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy

B. Moriyama, A. Owusu Obeng, J. Barbarino, S. R. Penzak, S. A. Henning, S. A. Scott, J. A.G. Agúndez, J. R. Wingard, H. L. McLeod, T. E. Klein, S. J. Cross, K. E. Caudle, T. J. Walsh

Research output: Contribution to journal › Article › peer-review

288 Scopus citations

Abstract

Voriconazole, a triazole antifungal agent, demonstrates wide interpatient variability in serum concentrations, due in part to variant CYP2C19 alleles. Individuals who are CYP2C19 ultrarapid metabolizers have decreased trough voriconazole concentrations, delaying achievement of target blood concentrations; whereas poor metabolizers have increased trough concentrations and are at increased risk of adverse drug events. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for the use of voriconazole for treatment based on CYP2C19 genotype (updates at https://cpicpgx.org/guidelines/ and www.pharmgkb.org).

Original language	English
Pages (from-to)	45-51
Number of pages	7
Journal	Clinical Pharmacology and Therapeutics
Volume	102
Issue number	1
DOIs	https://doi.org/10.1002/cpt.583
State	Published - 1 Jul 2017

Access to Document

10.1002/cpt.583

Cite this

Moriyama, B., Obeng, A. O., Barbarino, J., Penzak, S. R., Henning, S. A., Scott, S. A., Agúndez, J. A. G., Wingard, J. R., McLeod, H. L., Klein, T. E., Cross, S. J., Caudle, K. E., & Walsh, T. J. (2017). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy. Clinical Pharmacology and Therapeutics, 102(1), 45-51. https://doi.org/10.1002/cpt.583

@article{446b9bc5df464cd6a79f0fe867ddaa98,

title = "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy",

abstract = "Voriconazole, a triazole antifungal agent, demonstrates wide interpatient variability in serum concentrations, due in part to variant CYP2C19 alleles. Individuals who are CYP2C19 ultrarapid metabolizers have decreased trough voriconazole concentrations, delaying achievement of target blood concentrations; whereas poor metabolizers have increased trough concentrations and are at increased risk of adverse drug events. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for the use of voriconazole for treatment based on CYP2C19 genotype (updates at https://cpicpgx.org/guidelines/ and www.pharmgkb.org).",

author = "B. Moriyama and Obeng, {A. Owusu} and J. Barbarino and Penzak, {S. R.} and Henning, {S. A.} and Scott, {S. A.} and Ag{\'u}ndez, {J. A.G.} and Wingard, {J. R.} and McLeod, {H. L.} and Klein, {T. E.} and Cross, {S. J.} and Caudle, {K. E.} and Walsh, {T. J.}",

note = "Publisher Copyright: {\textcopyright} 2016 American Society for Clinical Pharmacology and Therapeutics",

year = "2017",

month = jul,

day = "1",

doi = "10.1002/cpt.583",

language = "English",

volume = "102",

pages = "45--51",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Wiley-Blackwell",

number = "1",

}

Moriyama, B, Obeng, AO, Barbarino, J, Penzak, SR, Henning, SA, Scott, SA, Agúndez, JAG, Wingard, JR, McLeod, HL, Klein, TE, Cross, SJ, Caudle, KE & Walsh, TJ 2017, 'Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy', Clinical Pharmacology and Therapeutics, vol. 102, no. 1, pp. 45-51. https://doi.org/10.1002/cpt.583

TY - JOUR

T1 - Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy

AU - Moriyama, B.

AU - Obeng, A. Owusu

AU - Barbarino, J.

AU - Penzak, S. R.

AU - Henning, S. A.

AU - Scott, S. A.

AU - Agúndez, J. A.G.

AU - Wingard, J. R.

AU - McLeod, H. L.

AU - Klein, T. E.

AU - Cross, S. J.

AU - Caudle, K. E.

AU - Walsh, T. J.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Voriconazole, a triazole antifungal agent, demonstrates wide interpatient variability in serum concentrations, due in part to variant CYP2C19 alleles. Individuals who are CYP2C19 ultrarapid metabolizers have decreased trough voriconazole concentrations, delaying achievement of target blood concentrations; whereas poor metabolizers have increased trough concentrations and are at increased risk of adverse drug events. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for the use of voriconazole for treatment based on CYP2C19 genotype (updates at https://cpicpgx.org/guidelines/ and www.pharmgkb.org).

AB - Voriconazole, a triazole antifungal agent, demonstrates wide interpatient variability in serum concentrations, due in part to variant CYP2C19 alleles. Individuals who are CYP2C19 ultrarapid metabolizers have decreased trough voriconazole concentrations, delaying achievement of target blood concentrations; whereas poor metabolizers have increased trough concentrations and are at increased risk of adverse drug events. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for the use of voriconazole for treatment based on CYP2C19 genotype (updates at https://cpicpgx.org/guidelines/ and www.pharmgkb.org).

UR - http://www.scopus.com/inward/record.url?scp=85018532893&partnerID=8YFLogxK

U2 - 10.1002/cpt.583

DO - 10.1002/cpt.583

M3 - Article

C2 - 27981572

AN - SCOPUS:85018532893

SN - 0009-9236

VL - 102

SP - 45

EP - 51

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 1

ER -

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy

Abstract

Access to Document

Fingerprint

Cite this